Clinical trials: Heart Transplantation
Acute Graft Rejection
Magnetic Resonance Elastography of Cardiac Transplant Rejection
Magnetic Resonance Elastography (MRE) for cardiac transplant patients.
- Trial name
- NCT02266914
- Testing
- Magnetic Resonance Elastography driver
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ohio State University
Heart Failure, Congestive
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
Heart failure is a condition in which the heart is unable to pump enough blood to the body's other organs. A heart transplant may be necessary for some individuals with end-stage heart failure.
- Trial name
- NCT00383630
- Testing
- Intramyocardial injection of bone marrow mononuclear cells, Intramyocardial injection of CD34+ selected bone marrow mononuclear cells, LVAD alone
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Cardiorenal Syndrome, Chronic Allograft Nephropathy
Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac…
- Trial name
- NCT01265615
- Testing
- Paricalcitol, Calcitriol, Cholecalciferol
- Where
- 2 sites in Netherlands, Russia
- Volunteers
- 109 people
- Sponsor
- Ural State Medical University
Patients With Post Orthotopic Heart Transplantation Status
iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.
The primary purpose of this study is to measure the level of an enzyme in a patient's heart called inducible nitric oxide synthase(iNOS) using Positron Emission Tomography (PET) imaging with a radioactive tracer called 18F-NOS.
- Trial name
- F-NOS (NCT01066637)
- Testing
- [18F](+/-)NOS
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Ischemic Heart Disease, Bone Marrow Cells
Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease
The purpose of this study evaluate the effect of the method of administration of autologous bone marrow mononuclear cells for the duration of of functioning aorto-coronary bypass grafts in the surgical treatment of coronary heart…
- Conditions
- Ischemic Heart Disease, Bone Marrow Cells, Coronary Artery Bypass Grafting (CABG), Heart Failure, Diastolic
- Trial name
- TAMIS (NCT02059512)
- Testing
- Group 1, Group 0, Group 2
- Where
- Russia
- Volunteers
- 117 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Cytomegalovirus Disease, Cytomegalovirus Infections
Letermovir Use in Heart Transplant Recipients
This is an open label trial in which letermovir will be given as prophylaxis for the prevention of cytomegalovirus (CMV) infection and disease to all heart transplants who are at risk for cytomegalovirus.
- Conditions
- Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity
- Trial name
- NCT04904614
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Tufts Medical Center
Heart Transplant
Impact of Evolocumab in Cardiac Transplant Patients With CAV
Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of a transplanted heart. Evolocumab (Repatha) is an FDA-approved drug for lowering low density lipoprotein (LDL) in patients who have not received a…
- Trial name
- NCT03944577
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Nebraska
Heart Transplantation
Multi-Drug Desensitization Protocol for Heart Transplant Candidates
Background: Patients may develop antibodies (human leukocyte antigen [HLA] alloantibodies) to other human tissues via pregnancy, transfusions or previous transplantation, which limits the ability to find an acceptable donor heart…
- Trial name
- NCT01556347
- Testing
- Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Providence Health & Services
Graft Rejection, Kidney Failure
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal…
- Trial name
- NCT00369382
- Testing
- cyclosporine or tacrolimus, sirolimus
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Heart Transplantation
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.
This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and steroids, in patients receiving a heart transplant.
- Trial name
- NCT02091414
- Testing
- mycophenolate mofetil (MMF), cyclosporine A (CsA), corticosteroids
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Organ Transplant
DCD IIT: Evaluating the Safety of Utilizing Donor Hearts From Donation After Circulatory Death (DCD) Donors
The purpose the research is to evaluate whether patients who receive a Donation after Circulatory Death (DCD) heart for cardiac transplantation using either normothermic regional perfusion (NRP) or direct procurement and…
- Trial name
- NCT05462041
- Testing
- DBD Donor Heart Transplantation, DCD Donor Heart Transplantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cedars-Sinai Medical Center
Heart Failure
HCV Positive Heart Donors
Study subjects active on the waiting list for a heart transplant at the NYU Langone Transplant Institute who are hepatitis C (HCV) negative will receive a heart transplant from a donor who tests positive for HCV.
- Trial name
- NCT03382847
- Testing
- Transplant with HCV positive donor, followed by surveillance and treatment of viremia
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Cardiac Transplant Disorder
Don't Throw Your Heart Away: Patient Study 4
This empirical study tests whether transplant center performance data that reflect center donor acceptance rates influence patients and their family members to evaluate centers with high organ decline rates less favorably than…
- Trial name
- NCT04809051
- Testing
- Stratified Transplant Survival Metric, SRTR Information Format
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Carnegie Mellon University
Primary Heart Transplant, Heart Transplantation
Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation
The primary objective is to evaluate the efficacy of desensitization therapy, which includes VELCADE® (bortezomib) and plasmapheresis, on select sensitized patients awaiting heart transplantation.
- Conditions
- Primary Heart Transplant, Heart Transplantation, Heart Transplant
- Trial name
- NCT01769443
- Testing
- bortezomib, plasmapheresis
- Where
- 14 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Function and Chronic Allograft Vasculopathy
SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
A controlled, randomized, open-label, multicenter study evaluating if early initiation of everolimus and early elimination of cyclosporine in de novo heart transplant recipients can improve long-term renal function and slow down…
- Trial name
- SCHEDULE (NCT01266148)
- Testing
- Cyclosporine, Mycophenolate mofetil, Corticosteroids
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
Heart Transplant
Heart EXPAND Continued Access Protocol
The OCS™ Heart System will be used to preserve and assess donor hearts that do not meet current standard donor heart acceptance criteria for transplantation in this continued access protocol.
- Trial name
- NCT03835754
- Testing
- OCS Heart System
- Where
- 12 sites in United States
- Volunteers
- 75 people
- Sponsor
- TransMedics
Cardiac Transplant Disorder
Don't Throw Your Heart Away: Clinician Study 3
Publicly available outcome assessments for transplant programs do not make salient that some programs tend to reject many of the hearts they are offered, whereas other programs accept a broader range of donor offers.
- Trial name
- NCT04455893
- Testing
- Stratified Transplant Survival
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Carnegie Mellon University
Heart Diseases, Heart Transplantation
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
The purpose of this study is to assess the safety and efficacy of tacrolimus in de novo heart transplantation.
- Trial name
- NCT00157014
- Testing
- Tacrolimus, Cyclosporine, Mycophenolate mofetil
- Where
- 13 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Astellas Pharma Inc
DiGeorge Anomaly, DiGeorge Syndrome
Thymus Transplantation Dose in DiGeorge #932
One purpose of this study is to determine whether the amount of cultured thymus tissue implanted into DiGeorge anomaly infants has any effect on the immune outcome.
- Conditions
- DiGeorge Anomaly, DiGeorge Syndrome, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
- Trial name
- NCT00576836
- Testing
- Cultured Thymus Tissue Implantation (CTTI), Cultured Thymus Tissue Implantation with Parathyroid Transplantation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Heart Failure, Cardiomyopathy
The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation
The main purpose of this research is to determine whether injecting mesenchymal precursor cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD) is safe.
- Conditions
- Heart Failure, Cardiomyopathy, Ventricular Dysfunction
- Trial name
- NCT01442129
- Testing
- MPC Intramyocardial injection, Control Solution
- Where
- 11 sites in United States
- Volunteers
- 30 people
- Sponsor
- Deborah Ascheim